Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up - Lasagna, A.; Lilleri, D.; Agustoni, F.; Percivalle, E.; Borgetto, S.; Alessio, N.; Comolli, G.; Sarasini, A.; Bergami, F.; Sammartino, J.C.; Ferrari, A.; Zavaglio, F.; et al. (ESMO open, 2022)
Keywords: B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - immunology; BNT162b2 anti-SARS-CoV-2 vaccine; cancer; COVID-19 - immunology; COVID-19 - prevention & control; Follow-Up Studies; Humans; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - immunology; Immunity, Cellular - drug effects; Immunity, Humoral - drug effects; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - immunology; Neoplasms - drug therapy; Neoplasms - immunology; neutralizing antibody; Original Research; PD-1/PD-L1 inhibitors; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; SARS-CoV-2 - immunology; spike-specific T-cell response; third dose; neutralizing antibody; BNT162b2 anti-SARS-CoV-2 vaccine; spike-specific T-cell response; cancer; PD-1/PD-L1 inhibitors; third dose